SNY - Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate
2024-05-13 10:09:30 ET
More on Sanofi, Fulcrum
- Sanofi Q1: Wait And See For Now (Downgrade)
- Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade)
- Sanofi 2024 Q1 - Results - Earnings Call Presentation
- Biggest stock movers today: ARM, ZK, TME, GME, and more
- Fulcrum Therapeutics GAAP EPS of -$0.43 in-line